GlassScriptPhysician profile
Kushagra Maini
NPI 1932620259
$14,945.08
in general payments reported to CMS, 2019-2025
34 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $86.53 · 2021: $7,510 · 2022: $4,315 · 2023: $2,330 · 2024: $428 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082 · Travel and Lodging: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.80 |
| Travel and Lodging | $798.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,307.07 | 2021-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Accurian |
| Abbott Laboratories | $2,849.26 | 2021-2025 | Proclaim, Eterna |
| Nevro Corp. | $252.70 | 2021-2024 | Senza |
| Inari Medical, INC. | $196.36 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Teva Pharmaceuticals USA, INC. | $188.55 | 2019-2023 | Austedo |
| Avanos Medical | $133.12 | 2021-2022 | |
| Greenwich Biosciences, INC. | $118.74 | 2019-2021 | |
| Boston Scientific Corporation | $100.15 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Alexion Pharmaceuticals, INC. | $97.96 | 2019-2025 | Ultomiris |
| Abbvie INC. | $92.67 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $61.88 | 2023 | |
| Pfizer INC. | $50.53 | 2019-2024 | |
| Heraeus Medical, LLC. | $39.29 | 2025 | |
| Vertos Medical, INC. | $38.99 | 2023-2024 | Mild Device Kit |
| Si-Bone, INC. | $33.88 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $32.23 | 2025 | Prolate, Tanlor, Nalocet |
| Sanofi-Aventis U.S. LLC | $23.85 | 2023 | |
| Spr Therapeutics, INC | $23.51 | 2023 | Sprint Pns System |
| Averitas Pharma INC. | $23.36 | 2024 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $23.12 | 2023 | Rexulti |
| Acadia Pharmaceuticals INC | $22.75 | 2022 | |
| Painteq LLC | $22.03 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $20.84 | 2024 | |
| Argenx US, INC. | $19.91 | 2023 | Vyvgart |
| Akcea Therapeutics, INC. | $19.75 | 2019 | |
| Neurelis, INC. | $19.50 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.83 | 2023 | Onpattro |
| Acacia Pharma INC | $18.32 | 2021 | |
| Ucb, INC. | $17.94 | 2023 | |
| Livanova USA, INC. | $17.07 | 2020 | |
| Saluda Medical Americas, INC. | $16.59 | 2024 | Evoke |
| Nalu Medical, INC. | $15.47 | 2021 | |
| Cala Health, INC. | $14.55 | 2022 | |
| Relievant Medsystems, INC. | $14.31 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kushagra Maini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.